<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">OJPed</journal-id><journal-title-group><journal-title>Open Journal of Pediatrics</journal-title></journal-title-group><issn pub-type="epub">2160-8741</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ojped.2015.54048</article-id><article-id pub-id-type="publisher-id">OJPed-61976</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Acute Chest Syndrome in Children with Sickle Cell Anaemia: An Audit in Port Harcourt, Nigeria
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>nnocent</surname><given-names>O. George</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Chika</surname><given-names>N. Aiyedun</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>Department of Paediatrics, University of Port Harcourt Teaching Hospital, Port Harcourt, Nigeria</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>geonosdemed@yahoo.com(NOG)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>29</day><month>10</month><year>2015</year></pub-date><volume>05</volume><issue>04</issue><fpage>320</fpage><lpage>325</lpage><history><date date-type="received"><day>3</day>	<month>November</month>	<year>2015</year></date><date date-type="rev-recd"><day>accepted</day>	<month>14</month>	<year>December</year>	</date><date date-type="accepted"><day>17</day>	<month>December</month>	<year>2015</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Acute chest syndrome (ACS) is a leading cause of death from sickle cell disease worldwide accounting for about 25% of all deaths. The aim of this study was to determine the prevalence, clinical features and outcome in Port Harcourt, Nigeria. Materials and Methods:
   A retrospective cohort study during a five year period. Records of all patients with sickle cell anaemia (SCA) admitted into the Wards were examined. Those enrolled for the study satisfied two criteria: 1) lower respiratory tract symptoms and 2) new pulmonary infiltrates on the chest radiograph. Sociodemographics, genotype, clinical and laboratory features, treatment given and outcome were obtained. Data were analysed by descriptive statistics. Variables were compared by students’ t-test. P value ≤ 0.05 was regarded as significant. 
  Results:
   A total of 345 children with sickle cell anaemia were admitted during the 5 year period. Twelve of them had acute chest syndrome (3.5%). Majority 7 (58.3%) of them were under 5 years. There were more males 8 (66.7%) than female 4 (33.3%). The most common clinical features were fever 12 (100%), cough 10 (83.3%), chest pain 5 (41.7%), 
  pulmonary consolidation 12 (100%), and respiratory distress 12 (100%). 
  The admitting diagnosis were bronchopneumonia 6 (50%), severe malaria 3 (25%) and vaso-occlusive crises 3 (25%). There were
   very high levels of leukocyte. Received 
  ceftriaxone or ampicillin
   
   + gentamicin &#177; oral erythromycin), paracetamol 12 (100%), ibuprofen 8 (66.7%), tramadol 3 (25.0%),
   pentazocine 8 (66.7%) and blood transfusion 9 (75%). 
  The average length of stay was 7 days (range 4 - 14 days). One patient died (8.3%). 
  Conclusion: ACS is not uncommon in children with SCA in Port Harcourt. Education of parents on the need to recognize early symptoms of the disease is essential. Clinicians must be trained to correctly diagnose and manage it promptly and efficiently to avoid its related disastrous consequences.
 
</p></abstract><kwd-group><kwd>Acute Chest Syndrome</kwd><kwd> Clinical Features</kwd><kwd> Treatment</kwd><kwd> Outcome</kwd><kwd> Port Harcourt</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Sickle cell anemia is one of the most prevalent genetic diseases worldwide [<xref ref-type="bibr" rid="scirp.61976-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.61976-ref2">2</xref>] . It frequently poses a task to health care providers for whom the disease can be considered one of the most significant haemoglobinopathies. Amid a diverse range of complications of varying complexity, none can become as rapidly disastrous as acute chest syndrome (ACS) [<xref ref-type="bibr" rid="scirp.61976-ref2">2</xref>] . It is the leading cause of death from sickle cell disease (SCD) worldwide accounting for about 25% of all deaths.</p><p>ACS is defined as a new pulmonary infiltrate on chest X-ray, combined with one or more manifestations such as fever, cough, sputum production, tachypnoea, dyspnoea, or new onset hypoxia [<xref ref-type="bibr" rid="scirp.61976-ref3">3</xref>] . It has a varied pathogenesis that includes occlusion of the pulmonary vascular bed by sickle erythrocytes, infection, embolized marrow fat, and lung infarction. It often follows a painful event, particularly in adults and although many pathologic processes may coexist establishing a specific cause is often difficult. Infections due to bacteria like Mycoplasma, Chlamydia, Legionella, Streptococcus pneumoniae, Haemophilus influenzae and viruses are more likely in children [<xref ref-type="bibr" rid="scirp.61976-ref4">4</xref>] .</p><p>ACS is a frequent cause of hospitalization for patients with SCD. In the cooperative study of sickle cell disease (CSSCD), the mortality rate in patients with ACS was 1.1% in children [<xref ref-type="bibr" rid="scirp.61976-ref5">5</xref>] . In another multicenter study in the USA [<xref ref-type="bibr" rid="scirp.61976-ref3">3</xref>] , the national ACS study group analyzed 671 episodes of ACS in 538 patients, with a mortality rate of 3%. In a 5-year study on the impact of seasonal variation of climatic factors on morbidities associated with vaso-occlusive crisis (VOC) among patients with sickle cell anaemia (SCA) in Maiduguri and Kano Teaching Hospitals, Nigeria, Ahmed et al. [<xref ref-type="bibr" rid="scirp.61976-ref6">6</xref>] found 56 episodes of ACS out of 2652 patients of VOC, giving a proportion of 2.11%.</p><p>Treatment for ACS is largely supportive in most cases. Early detection and supportive treatment may limit its severity and prevent death. Treatment includes continuous pulse oximetry and delivery of supplemental oxygen to patients with hypoxemia, adequate pain management, empiric antimicrobial therapy, monitoring of the haemoglobin concentration, blood transfusion, and maintenance of good hydration [<xref ref-type="bibr" rid="scirp.61976-ref7">7</xref>] .</p><p>There are limited data on ACS in Nigeria and none has been reported in Port Harcourt, the capital city of Rivers state, Nigeria. In view of this, we decided to retrospectively audit all children with sickle cell anaemia with diagnosis of ACS. We hope to establish the prevalence, common clinical features and outcome of treatment in Port Harcourt, Nigeria.</p></sec><sec id="s2"><title>2. Materials and Methods</title><p>A retrospective cohort study during a five year period beginning January 2009 and ending December 2014 was done. The records of all patients with sickle cell anaemia who were admitted to the Children Emergency and Paediatric Wards of the University of Port Harcourt Teaching Hospital (UPTH), Port Harcourt, Nigeria, during the period stated by the study were carefully examined. Ethical clearance was obtained from the Ethical Committee of UPTH. Those admitted to the study satisfied two criteria: 1) lower respiratory tract symptoms and 2) new pulmonary infiltrates on the chest radiograph. Information obtained included age, gender, haemoglobin genotype, clinical features, laboratory parameters (full blood count, chest X-ray and thick and thin film for malaria parasite), treatment given and outcome. Data were spread in excel sheets and analysis done by descriptive statistics in form of means and percentages. Variables were compared by student t test. P value ≤ 0.05 was regarded as significant.</p></sec><sec id="s3"><title>3. Results</title><p>A total of 345 children with Sickle cell anaemia were admitted during the 5 year period. Twelve of them satisfied being diagnosed for acute chest syndrome (3.5%). They were aged 3 - 15 years with 7 (58.3%) of them under 5 years. There were more males 8 (66.7%) than female 4 (33.3%) (<xref ref-type="table" rid="table1">Table 1</xref>).</p><p>The presenting symptoms are reported in <xref ref-type="table" rid="table2">Table 2</xref>. The most common presenting symptoms were fever 12 (100%), cough 10 (83.3%), and chest pain 5 (41.7%). Two (16.7%) of the patients had wheeze/rhonchi. The most common physical findings were pulmonary consolidation 12 (100%), fever 12 (100%) and signs of respiratory distress 12 (100%). The admitting diagnosis were bronchopneumonia 6 (50%), severe malaria 3 (25%) and vaso-occlusive crises 3 (25%) but subsequently developed ACS during their hospital stay.</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> General characteristics of the study group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Characteristics</th><th align="center" valign="middle" >Number (12)</th><th align="center" valign="middle" >Percentage (%)</th></tr></thead><tr><td align="center" valign="middle" >Age group (years)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;5</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >58.3</td></tr><tr><td align="center" valign="middle" >&gt;5</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >41.7</td></tr><tr><td align="center" valign="middle" >Gender</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Male</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >66.7</td></tr><tr><td align="center" valign="middle" >Female</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >33.3</td></tr><tr><td align="center" valign="middle" >Regular follow up</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >25</td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >75</td></tr><tr><td align="center" valign="middle" >On antibiotics prophylaxis</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >100</td></tr></tbody></table></table-wrap><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Clinical features of ACS</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Clinical features</th><th align="center" valign="middle" >Number</th><th align="center" valign="middle" >Percentage (%)</th></tr></thead><tr><td align="center" valign="middle" >Initial symptoms</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Fever</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >100</td></tr><tr><td align="center" valign="middle" >Cough</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >83.3</td></tr><tr><td align="center" valign="middle" >Chest pain</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >41.7</td></tr><tr><td align="center" valign="middle" >Bone pains</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >25</td></tr><tr><td align="center" valign="middle" >Weakness</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >33.3</td></tr><tr><td align="center" valign="middle" >Abdominal pains</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >25</td></tr><tr><td align="center" valign="middle" >Vomiting</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >16.7</td></tr><tr><td align="center" valign="middle" >Wheeze</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >16.7</td></tr><tr><td align="center" valign="middle" >Clinical signs</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Anaemia</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >91.7</td></tr><tr><td align="center" valign="middle" >Jaundice</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >41.7</td></tr><tr><td align="center" valign="middle" >Haemoglobinuria</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >8.3</td></tr><tr><td align="center" valign="middle" >Respiratory distress</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >100</td></tr><tr><td align="center" valign="middle" >Bone tenderness</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >16.7</td></tr><tr><td align="center" valign="middle" >Rhonchi</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >16.7</td></tr><tr><td align="center" valign="middle" >Chest X-ray findings</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Lobar consolidation</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >33.3</td></tr><tr><td align="center" valign="middle" >Diffuse consolidation</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >66.7</td></tr><tr><td align="center" valign="middle" >Malarial parasitaemia</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Negative</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >16.7</td></tr><tr><td align="center" valign="middle" >Positive</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >83.3</td></tr></tbody></table></table-wrap><p>ACS = Acute chest syndrome.</p><p>Laboratory test results showed very high levels of leukocytes, neutrophils and relatively high packed cell volume (<xref ref-type="table" rid="table3">Table 3</xref>). CRP and LDH results were not available. Chest X-ray mainly showed diffuse pulmonary consolidations 8(66.7%).</p><p>Patients were placed on two to three antibiotics: ceftriaxone or ampicillin + gentamicin &#177; oral erythromycin) (<xref ref-type="table" rid="table4">Table 4</xref>). Analgesics in the form of paracetamol 12 (100%), ibuprofen 8 (66.7%). tramadol 3 (25.0%) and pentazocine 8 (66.7%) were administered. Nine (75%) had blood transfusion. The average length of stay (LOS) was 7 days (range 4 - 14 days). One patient died giving a mortality rate of 8.3%.</p></sec><sec id="s4"><title>4. Discussion</title><p>This study showed that ACS accounted for 3.5% of SCA children admitted in our hospital. This rate is lower than the 10% - 20% rate of hospital admissions reported by Miller and Gladwin in their review [<xref ref-type="bibr" rid="scirp.61976-ref8">8</xref>] . Also, Alkali and Ambe [<xref ref-type="bibr" rid="scirp.61976-ref9">9</xref>] in their retrospective study reported that of the 120 cases of SCA admitted 80 were found to have ACS. This lower rate of ACS in this study may be underestimated as some unknown SCA patients may have</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Laboratory parameters of children with ACS</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Laboratory parameters</th><th align="center" valign="middle" >Steady state</th><th align="center" valign="middle" >At presentation</th><th align="center" valign="middle" >P-value</th></tr></thead><tr><td align="center" valign="middle" >Packed cell volume</td><td align="center" valign="middle" >21 &#177; 2.1</td><td align="center" valign="middle" >23 &#177; 3.4</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >Leucocytes mm<sup>3 </sup></td><td align="center" valign="middle" >12,541 &#177; 3.8</td><td align="center" valign="middle" >27,437 &#177; 5.1</td><td align="center" valign="middle" >&lt;0.05</td></tr><tr><td align="center" valign="middle" >Neutrophil</td><td align="center" valign="middle" >45 &#177; 2.8</td><td align="center" valign="middle" >48 &#177; 3.2</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >Platelet</td><td align="center" valign="middle" >180 &#177; 5.8</td><td align="center" valign="middle" >182.4.3</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >Eosinophil</td><td align="center" valign="middle" >2.3 &#177; 0.3</td><td align="center" valign="middle" >3.4 &#177; 0.8</td><td align="center" valign="middle" >&gt;0.05</td></tr></tbody></table></table-wrap><p>ACS = Acute chest syndrome.</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Treatment and outcome of children with ACS</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Treatment and outcome</th><th align="center" valign="middle" >Number</th><th align="center" valign="middle" >Percentage (%)</th></tr></thead><tr><td align="center" valign="middle" >Antibiotics therapy</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Ceftriaxone</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >66.7</td></tr><tr><td align="center" valign="middle" >Ampicillin</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >41.7</td></tr><tr><td align="center" valign="middle" >Gentamycin</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >58.3</td></tr><tr><td align="center" valign="middle" >Erythromycin</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >16.7</td></tr><tr><td align="center" valign="middle" >Antimalaria</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >100</td></tr><tr><td align="center" valign="middle" >Analgesics</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Ibuprofen</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >66.7</td></tr><tr><td align="center" valign="middle" >Tramadol</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >25</td></tr><tr><td align="center" valign="middle" >Pentazocine</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >66.7</td></tr><tr><td align="center" valign="middle" >Oxygen</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >8.3</td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >91.7</td></tr><tr><td align="center" valign="middle" >Transfusion</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >25</td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >75</td></tr><tr><td align="center" valign="middle" >Duration of admission (days)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;5</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >16.7</td></tr><tr><td align="center" valign="middle" >&gt;5</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >83.3</td></tr></tbody></table></table-wrap><p>ACS = Acute chest syndrome.</p><p>presented with this condition without relevant laboratory workup and diagnosis and thus missed been enrolled. Furthermore, it is also possible that due to parents’ financial constraints, the only chest X-ray done during hospitalization could have been normal given that radiographic findings in some case of ACS may progress over time [<xref ref-type="bibr" rid="scirp.61976-ref5">5</xref>] .<sup> </sup></p><p>We observed a male predominance in line with previous studies [<xref ref-type="bibr" rid="scirp.61976-ref8">8</xref>] [<xref ref-type="bibr" rid="scirp.61976-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.61976-ref11">11</xref>] . Fever (100%), cough (83.3%) and chest pains (41.7%) were the main symptoms among our patients. This is in keeping with previous reports [<xref ref-type="bibr" rid="scirp.61976-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.61976-ref12">12</xref>] .</p><p>There was significantly high leukocyte counts 27,437 mm<sup>3</sup> compared with steady state leukocyte count of 12,541 mm<sup>3</sup> [P ≤ 0.05]. This may suggest that infection may precipitate the development of ACS among our patients, validating previous reports elsewhere [<xref ref-type="bibr" rid="scirp.61976-ref11">11</xref>] [<xref ref-type="bibr" rid="scirp.61976-ref13">13</xref>] [<xref ref-type="bibr" rid="scirp.61976-ref14">14</xref>] . It also has been reported in the literatures that microorganisms such as Streptococcus pneumonia, Chlamydiae pneumonia, Mycoplasma pneumonia, influenza virus A H1N1, parainfluenza virus, respiratory syncytial virus and coronavirus among others have been associated with ACS [<xref ref-type="bibr" rid="scirp.61976-ref5">5</xref>] . The predominant radiological finding in our study was diffuse lung involvement, in form of bronchopneumonia. This has been reported by Alkali and Ambe [<xref ref-type="bibr" rid="scirp.61976-ref9">9</xref>] .</p><p>All of our patients were initially diagnosed as bronchopneumonia, severe malaria and vaso-occlusive crisis but subsequently developed ACS. Several studies [<xref ref-type="bibr" rid="scirp.61976-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.61976-ref8">8</xref>] have shown that ACS may develop 1 - 3 days after admission for VOC as there may exist a close relationship between ACS and VOC.</p><p>In line with the literatures [<xref ref-type="bibr" rid="scirp.61976-ref15">15</xref>] [<xref ref-type="bibr" rid="scirp.61976-ref16">16</xref>] , our management of ACS included broad-spectrum antibiotics, analgesics, supplemental oxygen and transfusion. Early transfusion of SCA patients presenting with ACS should be encouraged, especially transfusion of packed red blood cells [<xref ref-type="bibr" rid="scirp.61976-ref17">17</xref>] .</p><p>The average duration of hospitalization of 7 days is comparable to the 7 days-duration reported by Bertholdt et al., [<xref ref-type="bibr" rid="scirp.61976-ref14">14</xref>] but lower than what has been reported by Vichinsky et al. [<xref ref-type="bibr" rid="scirp.61976-ref5">5</xref>] . Introduction of other supportive care in our practice like bronchodilators and incentive spirometry as elsewhere, along with systematic oxygen supplementation and early blood transfusion could substantially reduce the duration of hospital stay [<xref ref-type="bibr" rid="scirp.61976-ref8">8</xref>] [<xref ref-type="bibr" rid="scirp.61976-ref17">17</xref>] .</p><p>One of our patients died, hence a mortality rate of 8.3% which is higher than the 4% percentage obtained by Bertholdt et al. in Belgium [<xref ref-type="bibr" rid="scirp.61976-ref14">14</xref>] .</p></sec><sec id="s5"><title>5. Conclusion</title><p>ACS is not an uncommon complication among children with SCA in Port Harcourt, Nigeria. There is need to educate parents on the need to recognize early symptoms of the disease, and seek help promptly. More so, clinicians must be trained to correctly diagnose ACS, and manage it promptly and efficiently to avoid its related disastrous consequences.</p></sec><sec id="s6"><title>Cite this paper</title><p>Innocent O.George,Chika N.Aiyedun, (2015) Acute Chest Syndrome in Children with Sickle Cell Anaemia: An Audit in Port Harcourt, Nigeria. Open Journal of Pediatrics,05,320-325. doi: 10.4236/ojped.2015.54048</p></sec><sec id="s7"><title>NOTES</title></sec></body><back><ref-list><title>References</title><ref id="scirp.61976-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Taylor, I.C., Carter, F., Poulose, J., Rolle, S., Babu, S. and Crichlow, S. (2004) Clinical Presentation of Acute Chest Syndrome in Sickle Cell Disease. Postgraduate Medical Journal, 80, 346-349. http://dx.doi.org/10.1136/pgmj.2003.012781</mixed-citation></ref><ref id="scirp.61976-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Thomas, A.N., Pattison, C. and Serjeant, G.R. (1982) Causes of Death in Sickle Cell Disease in Jamaica. British Medical Journal, 285, 633-635.</mixed-citation></ref><ref id="scirp.61976-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Vichinsky, E.P., Neumayr, L.D., Earles, A.N., Williams, R., Lennette, E.T., Dean, D., et al. (2000) Causes and Outcomes of the Acute Chest Syndrome in Sickle Cell Disease. National Acute Chest Syndrome Study Group. The New England Journal of Medicine, 342, 1855-1865. http://dx.doi.org/10.1056/NEJM200006223422502</mixed-citation></ref><ref id="scirp.61976-ref4"><label>4</label><mixed-citation publication-type="book" xlink:type="simple">Lal, A. and Vichinsky, E.P. (2005) Sickle cell disease. In: Hoffbrand, A.V., Catovsky, D. and Tuddenham, E.G., Eds., Postgraduate Haematology, 5th Edition, Blackwell Publishing, Hoboken, 104-118. http://dx.doi.org/10.1002/9780470987056.ch7</mixed-citation></ref><ref id="scirp.61976-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Vichinsky, E.P., Styles, L.A., Colangelo, L.H., Wright, E.C., Castro, O. and Nickerson, B. (1997) Acute Chest Syndrome in Sickle Cell Disease: Clinical Presentation and Course. Cooperative Study of Sickle Cell Disease. Blood, 89, 1787-1792.</mixed-citation></ref><ref id="scirp.61976-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Ahmed, S.G., Kagu, M.B., Abjah, U.A. and Bukar, A.A. (2012) Seasonal Variations in Frequencies of Acute Vaso-Occlusive Morbidities among Sickle Cell Anaemia Patients in Northern Nigeria. Journal of Blood Disorders &amp; Transfusion, 3, 120. http://dx.doi.org/10.4172/2155-9864.1000120</mixed-citation></ref><ref id="scirp.61976-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Yusuf, B.J., Abba, A.A. and Tasiu, M. (2014) Acute Chest Syndrome. Sub-Saharan African Journal of Medicine, 1, 111-118. http://dx.doi.org/10.4103/2384-5147.138930</mixed-citation></ref><ref id="scirp.61976-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Miller, A.C. and Gladwin, M.T. (2012) Pulmonary Complications of Sickle Cell Disease. American Journal of Respiratory and Critical Care Medicine, 185, 1154-1165. http://dx.doi.org/10.1164/rccm.201111-2082CI</mixed-citation></ref><ref id="scirp.61976-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Alkali, M.B. and Ambe, J.P. (2015) Acute Chest Syndrome in Paediatric Patients with Sickle Cell Disease in Northeastern, Nigeria. Direct Research Journal of Health and Pharmacology, 3, 45-50.</mixed-citation></ref><ref id="scirp.61976-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Bernard, A.W., Yasin, Z. and Venkat, A. (2007) Acute Chest Syndrome of Sickle Cell Disease. Hospital Physician, 44, 5-23.</mixed-citation></ref><ref id="scirp.61976-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Castro, O., Brambilla, D.J., Thorington, B., Reindorf, C.A., Scott, R.B., Gillette, P., Vera, J.C. and Levy, P.S. (1994) The Acute Chest Syndrome in Sickle Cell Disease: Incidence and Risk Factors. The Cooperative Study of Sickle Cell Disease. Blood, 84, 643-649.</mixed-citation></ref><ref id="scirp.61976-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Lamarre, Y., Romana, M., Waltz, X., Lalanne-Mistrih, M.L., Tressières, B., Divialle-Doumdo, L., Hardy-Dessources, M.D., Vent-Schmidt, J., Petras, M., Broquere, C., et al. (2012) Hemorheological Risk Factors of Acute Chest Syndrome and Painful Vaso-Occlusive Crisis in Children with Sickle Cell Disease. Haematologica, 97, 1641-1647. http://dx.doi.org/10.3324/haematol.2012.066670</mixed-citation></ref><ref id="scirp.61976-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Sprinkle, R.H., Cole, T., Smith, S. and Buchanan, G.R. (1996) Acute Chest Syndrome in Children with Sickle Cell Disease. A Retrospective Analysis of 100 Hospitalized Cases. Journal of Pediatric Hematology/Oncology, 8, 105-110.</mixed-citation></ref><ref id="scirp.61976-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Bertholdt, S., Lê, P.Q., Heijmans, C., Huybrechts, S., Dedeken, L., Devalck, C., Schifflers, S. and Ferster, A. (2012) Respiratory Complications of Sickle Cell Anemia in Children: The Acute Chest Syndrome. Revue Médicale de Bruxelles, 33, 138-144.</mixed-citation></ref><ref id="scirp.61976-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Miller, S.T. (2011) How I Treat Acute Chest Syndrome in Children with Sickle Cell Disease. Blood, 117, 5297-5305.   http://dx.doi.org/10.1182/blood-2010-11-261834</mixed-citation></ref><ref id="scirp.61976-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Elenga, N., Cuadro, E., Martin, E., Cohen-Addad, N. and Basset, T. (2014) Associated Factors of Acute Chest Syndrome in Children with Sickle Cell Disease in French Guiana. International Journal of Pediatrics, 2014, Article ID: 213681.   http://dx.doi.org/10.1155/2014/213681</mixed-citation></ref><ref id="scirp.61976-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Nansseu, J.R., Noubiap, J.J., Ndoula, S.T., Zeh, A.F. and Monamele, C.G. (2013) What Is the Best Strategy for the Prevention of Transfusion-Transmitted Malaria in Sub-Saharan African Countries Where Malaria Is Endemic? Malaria Journal, 12, 465.  http://dx.doi.org/10.1186/1475-2875-12-465</mixed-citation></ref></ref-list></back></article>